## <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

## **Materials**

Antibodies	No (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	Not available	
name, catalogue number and RRID, if available.		

Cell materials	No (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	Not available	
Primary cultures: Provide species, strain, sex of	Not available	
origin, genetic modification status.		

Experimental animals	No (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID	Not available	
Animal observed in or captured from the field: Provide species, sex and age where possible	Not available	
Model organisms: Provide Accession number in repository (where relevant) OR RRID	Not available	

Plants and microbes	No (indicate where provided: section/paragraph)	n/a
<b>Plants:</b> provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	Not available	
<b>Microbes:</b> provide species and strain, unique accession number if available, and source	Not available	

Human research participants	No (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Not available	
equivalent committee(s), provide reference number		
for approval.		
Provide statement confirming informed consent	Not available	
obtained from study participants.		
Report on age and sex for all study participants.	Not available	

# <u>Design</u>

Charles	No finding and an amount of the first form and the	1-
Study protocol	No (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration	Not available	
number <b>OR</b> cite DOI in manuscript.		
Laboratory protocol	No (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-	Not available	
by-step protocols are available.		
Experimental study design (statistics details)	No (indicate where provided: section/paragraph)	n/a
State whether and how the following have been	indicate where provided section, paragraphy	,
done, <b>or</b> if they were not carried out.		
Sample size determination	Not available	
Randomisation	Not available	
Blinding	Not available	
Inclusion/exclusion criteria	Not available	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	Yes, see the '##U-Net segmentation results'	
Define whether data describe technical or biological	Yes, see the '##U-Net segmentation results'	
replicates	_	
Falcier	N. C. P	,
Ethics	No (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent	Not available	
committee(s), provide reference number for		
approval.		
Studies involving experimental animals: State details	Not available	
of authority granting ethics approval (IRB or	Not available	
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if	Not available	
relevant permits obtained, provide details of	-	
authority approving study; if none were required,		
explain why.		
Dual Use Research of Concern (DURC)	No (indicate where provided: section/paragraph)	n/a
		, a
	Not available	
If study is subject to dual use research of concern, state the authority granting approval and reference	Not available	

# **Analysis**

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is	Not Available	
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	Not Available	
tests.		

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	Not Available	
If data are publicly available, provide accession number in repository or DOI or URL.	Not Available	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Not Available	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.	Not Available	
If code is publicly available, provide accession number in repository, or DOI or URL.	Not Available	

# Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

 $Article\ Information: \underline{http://dx.doi.org/10.21037/atm-21-319}$